Sun Pharma introduces STARIZO in India for skin infections
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
The emergence of new infections in India is a growing concern
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
        Subscribe To Our Newsletter & Stay Updated